Optical Tomographic Imaging of Infantile Hemangiomas

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The investigators hypothesize that there are differences between infantile hemangiomas (IH) during the proliferating and involuting phases and in response to medical treatment that can be detected by optical tomography of these hemangiomas.

Condition or disease
Infantile Hemangioma

Detailed Description:

Infantile hemangiomas (IH) are common vascular growths that frequently arise in infants. The clinical presentation is variable, and some hemangiomas have the potential to cause disfiguring and even lifethreatening complications. While there is no FDA approved treatment for IH, certain medications have been shown to be effective in shrinking the growths. Unfortunately, there is no objective tool to monitor IH or to guide treatment. Such a tool would improve the management of these patients. A new handheld wireless device uses diffuse optical imaging (DOI) technology to measure blood flow characteristics.

The device has been used in studies to assess patients with breast cancer. Optical tomography has also been increasingly used to assess neurological function and pathology in newborn infants.

The goal of the investigators' study is to assess the utility of DOI for characterizing and monitoring IH. Fifteen IH will be assessed at three points in time as part of this study, comprising two groups: 'Natural History' and 'Treatment'. DOI measurements will be correlated with clinical findings and existing ultrasound measurements of the IH.

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Actual Enrollment :	15 participants
Observational Model:	Cohort
Time Perspective:	Other
Official Title:	Optical Tomographic Imaging of Infantile Hemangiomas
Study Start Date :	May 2012
Estimated Primary Completion Date :	January 1, 2018
Estimated Study Completion Date :	January 1, 2018

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Natural History
Treatment

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Difference in absolute total hemoglobin concentration ([THb]) of hemangioma and normal skin. [ Time Frame: Up to 2 years ]
   Measurements of absolute total hemoglobin concentration ([THb]) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.
2. Difference in tissue oxygen saturation (StO2) of hemangioma and normal skin. [ Time Frame: Up to 2 years ]
   Measurements of tissue oxygen saturation (StO2) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.

Secondary Outcome Measures :

1. Difference in absolute total hemoglobin concentration ([THb]) of hemangioma at different time points. [ Time Frame: Up to 2 years ]
   Measurements of absolute total hemoglobin concentration ([THb]) of the hemangioma are obtained at different time points and compared.
2. Difference in tissue oxygen saturation (StO2) of the hemangioma at different time points. [ Time Frame: Up to 2 years ]
   Measurements of tissue oxygen saturation (StO2) of the hemangioma are obtained at different time points and compared.

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	up to 7 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

All subjects will be recruited verbally from the pediatric dermatology faculty practices, clinics and inpatient services at CUMC/NYP (MSCHONY). In accordance with CUMC policy, researchers will not approach a patient for recruitment until that patient has been informed of the study by their treating physician who has ascertained the patient's willingness to discuss the study with the investigators.

Criteria

For the 'Natural History' Cohort, the following inclusion and exclusion criteria apply:

INCLUSION CRITERIA:

• Infants with IH who present to our practices within the first 2 months of life.
• IH of size > 2 cm in diameter
• IH located on area of skin that is accessible to contact by 4x2cm probe. Examples include the lateral face, forehead, scalp, trunk and areas of the extremities not overlying joints.

Infants with IH that do not necessitate either medical or surgical intervention at time of presentation.

EXCLUSION CRITERIA:

• IH of size <2 cm in diameter
• Complicated IH requiring medical or surgical intervention
• IH located within 2 cm of the eye

For the 'Treatment' Cohort, the following inclusion and exclusion criteria apply:

INCLUSION CRITERIA:

• Infants with IH who present to our practices within the first 2 months of life.
• IH of size >2 cm in diameter
• IH located on area of skin that is accessible to contact by 4x2cm probe. Examples include the lateral face, forehead,scalp, trunk and areas of the extremities not overlying joints.
• IH that necessitate medical intervention with either oral or topical betablockers.

EXCLUSION CRITERIA:

• IH <2 cm in size
• Complicated IH requiring surgical intervention
• IH located within 2 cm of the eye

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, New York
Columbia University Medical Center / Department of Dermatology
New York, New York, United States, 10032

Sponsors and Collaborators

Columbia University

Investigators

Principal Investigator:	Maria Garzon, MD	Columbia University

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Maria Garzon, Professor of Clinical Dermatology and Clinical Pediatrics, Columbia University
ClinicalTrials.gov Identifier:	NCT01673971 History of Changes
Other Study ID Numbers:	AAAJ1201
First Posted:	August 28, 2012
Last Update Posted:	August 1, 2017
Last Verified:	July 2017

Keywords provided by Maria Garzon, Columbia University:

hemangioma

Additional relevant MeSH terms:

Hemangioma; Hemangioma, Capillary; Port-Wine Stain; Neoplasms, Vascular Tissue; Neoplasms by Histologic Type	Neoplasms; Skin Abnormalities; Congenital Abnormalities; Skin Diseases